<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006400</url>
  </required_header>
  <id_info>
    <org_study_id>89</org_study_id>
    <secondary_id>N01 HB07150</secondary_id>
    <secondary_id>N01 HB07151</secondary_id>
    <secondary_id>N01 HB07152</secondary_id>
    <secondary_id>N01 HB07153</secondary_id>
    <secondary_id>N01 HB07154</secondary_id>
    <secondary_id>N01 HB07155</secondary_id>
    <secondary_id>N01 HB07156</secondary_id>
    <secondary_id>N01 HB07157</secondary_id>
    <secondary_id>N01 HB07158</secondary_id>
    <secondary_id>N01 HB07159</secondary_id>
    <secondary_id>N01 HB07160</secondary_id>
    <nct_id>NCT00006400</nct_id>
  </id_info>
  <brief_title>Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia</brief_title>
  <official_title>Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Heart, Lung, and Blood Institute (NHLBI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if hydroxyurea therapy is effective in the
      prevention of chronic end organ damage in pediatric patients with sickle cell anemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      In 1995, the Multicenter Study of Hydroxyurea (MSH) demonstrated that hydroxyurea is
      effective in decreasing the frequency of painful crises, hospitalizations for crises, acute
      chest syndrome, and blood transfusions by 50%. The recently completed phase II study of
      hydroxyurea in children (PED HUG) demonstrated that children have a response to hydroxyurea
      similar to that seen in adults in terms of increasing fetal hemoglobin levels and total
      hemoglobin, and decreasing complications associated with sickle cell anemia. In addition,
      this study demonstrated that the drug does not adversely affect growth and development
      between the ages of 5 and 15. A recently completed pilot study of hydroxyurea given to
      children between the ages of 6 months and 24 months demonstrated that the drug is tolerated
      well by small infant, and that the fetal hemoglobin switch can be forced to remain in the &quot;on
      position&quot; by hydroxyurea administration.

      A Special Emphasis Panel (SEP) met on April 12, 1996 to review the results of the MSH trial
      and the progress to date of the PED HUG study. The SEP recommended that NHLBI undertake the
      BABY HUG trial.

      DESIGN NARRATIVE:

      BABY HUG is a randomized, double-blind, placebo-controlled study to determine if hydroxyurea
      can prevent the onset of chronic end organ damage in young children with sickle cell anemia.
      Approximately 200 children with sickle cell disease will be recruited to receive either
      hydroxyurea or placebo. The children will be screened at study entry for signs of abnormal
      brain, kidney, pulmonary, and splenic function, and developmental milestones. They will then
      be randomly assigned to receive either hydroxyurea or placebo and followed yearly to assess
      chronic end organ damage of the major organ systems. The primary endpoint will be a 50%
      reduction in rates of damage to the major organs with surrogate markers of organ function
      during follow-up in Phase II of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>50% reduction in rates of damage to the major organs with surrogate markers of organ function</measure>
    <time_frame>Measured during follow-up evaluations</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">191</enrollment>
  <condition>Hematologic Diseases</condition>
  <condition>Anemia, Sickle Cell</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive hydroxyurea.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
    <description>Participants will receive hydroxyurea.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Majority fetal and sickle (FS or SF) hemoglobin pattern confirmed centrally by
             electrophoresis (screening may begin at 7 months of age)

        Exclusion Criteria:

          -  Chronic transfusion therapy

          -  Cancer

          -  Less than 5th percentile (10th percentile for the pilot study) height, weight, or head
             circumference for age

          -  Severe developmental delay (e.g., cerebral palsy or other mental retardation, Grade
             III/IV intraventricular hemorrhage)

          -  Stroke with neurological deficit

          -  Surgical splenectomy

          -  Participating in other clinical intervention trials

          -  Probable or known diagnosis of Hemoglobin S-Hereditary Persistence of Fetal Hemoglobin

          -  Known hemoglobin S-beta plus thalassemia (hemoglobin A present)

          -  Any condition or chronic illness, which in the opinion of the principal investigator,
             makes participation unadvised or unsafe

          -  Inability or unwillingness to complete baseline (pre-enrollment) studies, including
             blood or urine specimen collection, liver-spleen scan, abdominal sonogram,
             neurological examination, neuropsychological testing, or transcranial Doppler
             ultrasound (interpretable study not required, but confirmed velocity greater than 200
             cm/sec results in ineligibility)

          -  Previous or current treatment with hydroxyurea (HU) or another anti-sickling drug

          -  The following exclusion criteria are transient; patients can be re-evaluated for
             eligibility:

               1. Hemoglobin less than 6.0 gm/dL

               2. Reticulocyte count less than 80,000/cu mm if hemoglobin is less than 9 gm/dL

               3. Neutrophil count less than 2,000/cu mm

               4. Platelet count less than 130,000/cu mm

               5. Blood transfusion in the 2 months prior to study entry unless HbA is less than
                  10%

               6. ALT greater than twice the upper limit of normal

               7. Ferritin less than 10 ng/ml

               8. Serum creatinine greater than twice the upper limit of normal for age

               9. Bayley standardized mental score below 70
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherron Jackson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James F. Casella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lori Luchtman-Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rathi V. Iyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott T. Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUNY Health Science Center, Brooklyn</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sohail R. Rana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Howard University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zora R. Rogers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas SW Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce W Thompson, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trials and Surveys Corp</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julio Barredo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Winfred C. Wang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Courtney Thornburg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Howard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lori Luck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drexel University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. Clark Brown, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharada Sarnaik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan/Wayne State Univ.</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Health Science Center, Brooklyn</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas SW Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Heeney MM, Whorton MR, Howard TA, Johnson CA, Ware RE. Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol. 2004 Mar;26(3):179-84.</citation>
    <PMID>15125610</PMID>
  </reference>
  <reference>
    <citation>Thompson BW, Miller ST, Rogers ZR, Rees RC, Ware RE, Waclawiw MA, Iyer RV, Casella JF, Luchtman-Jones L, Rana S, Thornburg CD, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik S, Howard TH, Luck L, Wang WC. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer. 2010 Feb;54(2):250-5. doi: 10.1002/pbc.22269.</citation>
    <PMID>19731330</PMID>
  </reference>
  <results_reference>
    <citation>Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; BABY HUG investigators. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011 May 14;377(9778):1663-72. doi: 10.1016/S0140-6736(11)60355-3.</citation>
    <PMID>21571150</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang WC, Pavlakis SG, Helton KJ, McKinstry RC, Casella JF, Adams RJ, Rees RC; BABY HUG Investigators. MRI abnormalities of the brain in one-year-old children with sickle cell anemia. Pediatr Blood Cancer. 2008 Nov;51(5):643-6. doi: 10.1002/pbc.21612.</citation>
    <PMID>18478575</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller ST, Wang WC, Iyer R, Rana S, Lane P, Ware RE, Li D, Rees RC; BABY-HUG Investigators. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatr Blood Cancer. 2010 Feb;54(2):265-8. doi: 10.1002/pbc.22189.</citation>
    <PMID>19621454</PMID>
  </results_reference>
  <results_reference>
    <citation>Pavlakis SG, Rees RC, Huang X, Brown RC, Casella JF, Iyer RV, Kalpatthi R, Luden J, Miller ST, Rogers ZR, Thornburg CD, Wang WC, Adams RJ; BABY HUG Investigators. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatr Blood Cancer. 2010 Feb;54(2):256-9. doi: 10.1002/pbc.22282.</citation>
    <PMID>19813252</PMID>
  </results_reference>
  <results_reference>
    <citation>Thornburg CD, Rogers ZR, Jeng MR, Rana SR, Iyer RV, Faughnan L, Hassen L, Marshall J, McDonald RP, Wang WC, Huang X, Rees RC; BABY HUG Investigators. Adherence to study medication and visits: data from the BABY HUG trial. Pediatr Blood Cancer. 2010 Feb;54(2):260-4. doi: 10.1002/pbc.22324.</citation>
    <PMID>19856395</PMID>
  </results_reference>
  <results_reference>
    <citation>Ware RE, Rees RC, Sarnaik SA, Iyer RV, Alvarez OA, Casella JF, Shulkin BL, Shalaby-Rana E, Strife CF, Miller JH, Lane PA, Wang WC, Miller ST; BABY HUG Investigators. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. J Pediatr. 2010 Jan;156(1):66-70.e1. doi: 10.1016/j.jpeds.2009.06.060.</citation>
    <PMID>19880138</PMID>
  </results_reference>
  <results_reference>
    <citation>Wynn L, Miller S, Faughnan L, Luo Z, Debenham E, Adix L, Fish B, Hustace T, Kelly T, Macdermott M, Marasciulo J, Martin B, McDuffie J, Murphy M, Rackoff B, Reed C, Seaman P, Thomas G, Wang W. Recruitment of infants with sickle cell anemia to a Phase III trial: data from the BABY HUG study. Contemp Clin Trials. 2010 Nov;31(6):558-63. doi: 10.1016/j.cct.2010.08.007. Epub 2010 Aug 24.</citation>
    <PMID>20797449</PMID>
  </results_reference>
  <results_reference>
    <citation>Rogers ZR, Wang WC, Luo Z, Iyer RV, Shalaby-Rana E, Dertinger SD, Shulkin BL, Miller JH, Files B, Lane PA, Thompson BW, Miller ST, Ware RE; BABY HUG. Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood. 2011 Mar 3;117(9):2614-7. doi: 10.1182/blood-2010-04-278747. Epub 2011 Jan 7.</citation>
    <PMID>21217080</PMID>
  </results_reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2000</study_first_submitted>
  <study_first_submitted_qc>October 12, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2000</study_first_posted>
  <disposition_first_submitted>April 7, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>April 7, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 14, 2011</disposition_first_posted>
  <last_update_submitted>April 15, 2011</last_update_submitted>
  <last_update_submitted_qc>April 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jonathan Goldsmith, MD</name_title>
    <organization>NHLBI</organization>
  </responsible_party>
  <keyword>Blood Diseases</keyword>
  <keyword>Sickle Cell Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

